THERAPY DOSSIER · th-e832239934f8

Lysine acetylsalicylate (LAS)

Drug · Lysine salt of acetylsalicylic acid; ChEMBL parent is CHEMBL25 (aspirin). get_mechanism not queried for the salt; mechanism attributed to the parent acetylsalicylic acid (irreversible COX-1/COX-2 acetylation).

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: Lysine salt of acetylsalicylic acid; ChEMBL parent is CHEMBL25 (aspirin). get_mechanism not queried for the salt; mechanism attributed to the parent acetylsalicylic acid (irreversible COX-1/COX-2 acetylation).
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL1697753 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Lysine acetylsalicylate; L-lysine acetylsalicylate; Acetylsalicylate lysine; Acetylsalicylic acid lysinate; Aspegic; Flectadol; Venopirin; Aspirin dl-lysine
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01379079 ↗PHASE4completed

Aspirin AM or PM in Reduction of Tension (acetylsalicylic acid lysinate)

Hypertension · Cardiovascular Diseases

Enrolment: 290 · Results not recorded

NCT02929888 ↗PHASE2/PHASE3unknown

IV Lysine Acetylsalicylate Versus Oral Aspirin on Platelet Responsiveness in STEMI (ECCLIPSE-STEMI)

Acute Myocardial Infarction

Enrolment: 60 · Results not recorded

NCT02243137 ↗PHASE1completed

Lysine Acetylsalicylate Versus Prasugrel and Aspirin on Platelet Aggregation in Volunteers

Adverse Effect of Antithrombotic Drugs

Enrolment: 30 · Results not recorded

NCT00815126 ↗NAcompleted

Nasal Provocation Test With Lysine-Acetylsalicylate in ASA/NSAID Sensitivity

Aspirin Hypersensitivity · NSAIDs Hypersensitivity

Enrolment: 34 · Results not recorded

NCT02612480 ↗NAcompleted

Ticagrelor on Inflammatory Response to Human Endotoxemia (acetylsalicylic acid lysinate arm)

Endotoxemia

Enrolment: 40 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21933594 ↗2011Reported benefit

Lysine acetylsalicylate ameliorates lung injury in rats acutely exposed to paraquat.

RatChemical/toxinSprague-DawleyMalen = 75200 mg/kgAfter paraquat poisoning (early treatment)

Model: Paraquat poisoning (50 mg/kg intragastric) lung injury

Lysine acetylsalicylate reduced oxidative stress, apoptosis and fibrosis and ameliorated paraquat-induced lung injury.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…